PhD candidate @Gerschlab at the CGC of the @MPImoph and @TU_Dortmund. Fascinated by drug discovery and all things Ubiquitin.
Joined September 2022
- Tweets131
- Following184
- Followers102
- Likes1.4K
Niko Klink retweeted
New Parkinson’s disease paper:
Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of USP30 and a framework for DUB ligandability - published by @MalteGersch group @maxplanckpress in @Nature Struct. & Mol. Biol.
nature.com/articles/s41594-0…
Excited to share that our work on Parkinson's target USP30 has been published in Nature Structural & Molecular Biology! By combining DUB-domains onto USP30, we for the first time achieved crystallization with a small molecule (NK036) without Nanobodies! nature.com/articles/s41594-0…
Niko Klink retweeted
Fighting drug-resistant GIST!🚀 We developed innovative covalent KIT/PDGFRA inhibitors using structure-based design. Check out our latest J Med Chem publication! doi.org/10.1021/acs.jmedchem…
#CancerResearch #DrugDiscovery
Niko Klink retweeted
Kicking off the new year properly: In collaboration between the labs of @giuliosf and @alessiociulli we found that the efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells. Out in @CellChemBiol cell.com/cell-chemical-biolo…
Niko Klink retweeted
Read how deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children.
mpi-dortmund.mpg.de/news/new…
Niko Klink retweeted
Very excited to share that our manuscript on the "Discovery and mechanism of K63-linkage-directed deubiquitinase activity in USP53" was published today at Nature Chemical Biology @nchembio. Congratulations Kim, Kai, and all authors! nature.com/articles/s41589-0…
For all ubiquitin, deubiquitinase and chemical biology aficionados:
Here's a preprint from the lab introducing 2 new active DUBs in humans & a unique type of DUB activity one would miss with the widely used panels of free ubiquitin chains.
t.ly/GnRVv
Thread👇(1/10)
Niko Klink retweeted
Tomorrow, November 26, we are looking forward to hosting @georg_e_winter from @CeMM_News, Austrian Academy of Sciences, Vienna, at @crc1430 @unidue. Join us for his exciting talk on small-molecule degraders!
Niko Klink retweeted
“We’re very excited to see what people do with this”
AlphaFold3 is open at last go.nature.com/4fHAfio
I had such a great time at this years AEK autumn school on #degraders and bringing them towards clinical applications. Fantastic Talks from both academia and Industry. I learned alot, got to see old friends and made New ones. Im bringing home great memories and a bunch of notes!
Niko Klink retweeted
Caspase-2 is a condensate-mediated deubiquitinase in protein quality control: nature.com/articles/s41556-0…
Niko Klink retweeted
Looking for E3 / PROTAC / glue or DUB / DUBTAC substrates? Proxy-Ubiquitomics might be the way - applied here to USP30 @AndreasDamiano2 Hannah Jones @ProteomOX
biorxiv.org/cgi/content/shor… #biorxiv_molbio
Niko Klink retweeted
In this work, @alessiociulli, @dlzollman, and @UoDCeTPD design and validate a truncated CRBN construct, CRBNmidi, that enables crystallization and biophysical characterization of CRBN-binding ligands and degraders. #TPD #PROTAC
nature.com/articles/s41467-0…
Niko Klink retweeted
We’re delighted to be partnering with @AlleoLabs to accelerate DUB-focused drug discovery!
This collaboration will combine Alleo’s AI-based platform with our expertise in the DUB space to advance DUB-focused preclinical programmes.
➡ tinyurl.com/283d7o5o
Niko Klink retweeted
We are excited to share our latest work in context of the colaborative research consortium 1430 @Crc1430. A preprint is available on bioRxiv (doi.org/10.1101/2024.10.01.6…).
Niko Klink retweeted
Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma response - published by the Imig group in @FrontiersIn Molecular Biosciences
frontiersin.org/journals/mol…
Honored to have presented my and our @Gerschlab research at this great conference! Looking forward to two more days!
Great talk by @NikolasKlink from the @GerschLab at #GDChBioChem2024 #Biochemistry2024. He talked about his research into studying deubiquitinases with inhibitors and PROTACs. biorxiv.org/content/10.1101/…
Proud to share our work on this fascinating enzyme and inhibitor class, congrats to everyone involved! This story is definetly worth a read. Cant wait to hear Feedback on our DUB ligandability proposal aswell!
Interested in Ubiquitin, Parkinson’s disease therapy, mitochondria or DUB inhibitors? This preprint may be for you:
We show how the deubiquitinase USP30 can specifically be inhibited & introduce a framework for DUB ligandability.
biorxiv.org/content/10.1101/…
Thread👇 – with movie!!
Niko Klink retweeted
Our new paper demonstrating reversible ubiquitylation of DNA and RNA:
embopress.org/doi/full/10.10…
Niko Klink retweeted
❗📚💡 PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters
academic.oup.com/nar/advance…
#TPD #Targeted_Protein_Degradation
Niko Klink retweeted
📢New lab preprint: 2.05 A #cryoEM structure of UapA: unprecedented aspects of the elevator-type transport (incl. water, lipids) and regulatory roles of the N-tail. With Diallinas, Mikros labs. Kudos @broutzakis and all co-authors. @uni_muenster #SoN
biorxiv.org/content/10.1101/…